SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial

摘要: 4500 Background: SU011248 is an oral multi-targeted tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity through inhibition of PDGFR, VEGFR, KIT FLT3. Methods: 63 patients metastatic renal cell carcinoma (RCC) were treated repeat cycles orally at 50 mg daily for 4 weeks followed by a 2-week rest period. Eligibility included measurable disease, ECOG performance status 0 or 1, failure one prior cytokine-based therapy, adequate cardiac function. Results: The median age was 60 years 58 (92%) had nephrectomy. Best response to as assessed RECIST: Of 15 (24%) who achieved PR, 1 patient progressed 5 months 14 remain progression-free duration 6+ months. 29 best SD, (8%) reduction unidimensional measurement least 30% await confirmation status. Currently there are 32 on treatment continued PR/SD...